Agios Pharmaceuticals (AGIO) Research & Development (2012 - 2026)

Agios Pharmaceuticals' Research & Development history runs 15 years deep, the most recent figure standing at $81.1 million for Q1 2026.

• Quarterly Research & Development rose 11.55% year-over-year to $81.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $347.9 million (up 13.93% YoY) and the FY2025 annual result came in at $339.5 million, up 12.7% from the prior year.
• Research & Development was $81.1 million for Q1 2026 at Agios Pharmaceuticals, down from $88.1 million in the prior quarter.
• Across five years, Research & Development topped out at $91.9 million in Q2 2025 and bottomed at $65.0 million in Q3 2022.
• A 5-year average of $76.3 million and a median of $74.5 million in 2022 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development gained 25.98% — and 2024, when it dropped 11.47%.
• Agios Pharmaceuticals' Research & Development stood at $70.3 million in 2022, then advanced by 10.23% to $77.5 million in 2023, then rose by 6.87% to $82.8 million in 2024, then advanced by 6.33% to $88.1 million in 2025, then dropped by 7.85% to $81.1 million in 2026.
• Business Quant data shows AGIO's Research & Development at $81.1 million in Q1 2026, $88.1 million in Q4 2025, and $86.8 million in Q3 2025.